Fig. 1: PGDM1400, PGT121 and VRC07-523LS pharmacokinetics.
Serum levels of PGDM1400, PGT121 and VRC07-523LS as determined by BAMA. Mean values for each dose group with s.e.m. for PGDM1400 dosed alone (group 1, adults without HIV) (a), PGDM1400 and PGT121 dosed sequentially (group 2, adults without HIV) (b), PGDM1400, PGT121 and VRC07-523LS dosed sequentially (group 3A, adults with HIV) (c) and PGDM1400 and PGT121 dosed sequentially (group 3B, adults with HIV) (d). Dotted lines at the bottom indicate lower limit of detection of the assays, color-coded according to antibody. Each sample was measured in duplicate. Serum t1/2 of PGDM1400 is 20.8 days in adults without HIV when dosed alone, 17.4 days in adults without HIV when dosed in combination with PGT121 (P = 0.05) and 11 days in adults with HIV when dosed in combination. (Supplementary Tables 7 and 8). e, Concordance among PGDM1400, PGT121 and VRC07-523LS concentrations measured by binding and neutralizing antibody assays, shown exemplary for group 3A participants. Neutralizing assays used 6540.v4.c1, CH505TF.N334S.N160A.N280D.1 and CAP220.2.00_A8_5B to measure PGDM1400, PGT121 and VRC07-523LS concentrations, respectively. The concordance for PGDM1400, PGT121 and VRC07-523LS were each ρc = 0.98 in group 3A (substantial agreement)(Pearson’s correlation). The dotted line is the identity line. The solid line is the trend line. Data are colored by bNAb.
